Article

Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis

2018-02-28

Abstract excerpt

<h4>Aim: </h4> Metastatic prostate cancer (mPCa) has a poor outcome with median survival of two to five years. The use of androgen deprivation therapy (ADT) is a gold standard in management of this stage. Aim of this study is to analyze the prognostic value of PSA kinetics of patient treated with hormonal therapy related to survival from several published studies <h4>Method: </h4> Systematic review and meta-anal...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: abefb7c2-6295-55d8-a08c-c66051248658
DOI: 10.12688/f1000research.14026.1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysisDOI 10.12688/f1000research.14026.1Read

Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysisSemantic proximity Read

Early PSA Decline after Starting Second-Generation Hormone Therapy in the Post-Docetaxel Setting Predicts Cancer-Specific Survival in Metastatic Castrate-Resistant Prostate CancerSemantic proximity Read

Androgen deprivation therapy for prostate cancer: current status and future prospects.Semantic proximity Read

Risk of Secondary Malignancies in Patients with prostate cancer: A Systematic Review and Meta-analysisSemantic proximity Read

Recent trends in the management of advanced prostate cancerSemantic proximity Read

Significant associations of prostate cancer susceptibility variants with survival in patients treated with androgen-deprivation therapy.Semantic proximity Read

How the Management of Biochemical Recurrence in Prostate Cancer Will be Modified by the Concept of Anticipation and Incrementation of TherapySemantic proximity Read

Androgen Receptor Splice Variant 7 Detected by Immunohistochemical Is an Independent Poor Prognostic Marker in Men Receiving Adjuvant Androgen-Deprivation Therapy After Radical ProstatectomySemantic proximity Read

Early upregulation of AR and steroidogenesis enzyme expression after 3 months of androgen-deprivation therapy.Semantic proximity Read

Current State of Adjuvant Hormone Therapy in Prostate Cancer and in the Management of Pelvic Nodal Recurrence: A Narrative ReviewSemantic proximity Read

Effects of enzalutamide, apalutamide, and darolutamide in metastatic hormone-sensitive prostate cancer with or without docetaxel: a systematic review and network meta-analysisSemantic proximity Read

Androgen receptor and osteoglycin gene expression predicting prognosis of metastatic prostate cancerSemantic proximity Read